Clinical utility of serum procalcitonin in differentiation of pulmonary infections in the elderly populations

doi:10.3969/j.issn.1006-7795.2014.04.015

Abstract

Abstract:

Objective To investigate the clinical utility of serum procalcitonin(PCT) in the diagnosis of pulmonary infections in elderly populations due to different pathogens. Methods A retrospective review was conducted by collecting the clinical data and microbiological records of 166 aged patients(≥60) having pulmonary infections from January 2009 to December 2011, including bacterial pneumonia(92 cases, 50 Gram-negative bacteria and 42 Gram-positive bacteria), pulmonary candida infection(PC, 12 cases), active pulmonary tuberculosis infection(TB, 11 cases), Mycoplasma pneumoniae infection(MP, 31 cases), and viral pneumonia(20 cases). Furthermore, 12 healthy subjects who underwent the physical examination enrolled as the control group. The serum PCT levels and other biomarkers were determined. The non-parametric test was used to analyze the differences of PCT between the aforementioned groups while ROC curves to determine the best differentiating cut-off values. Results The PCT levels were significantly higher in all pulmonary infections but Mycoplasma pneumoniae than those in the control group(P<0.01). Moreover, the PCT levels in bacterial pneumonia and pulmonary candida infection indicated no significant difference(χ²=447.0, P=0.285), however, its levels in bacterial pneumonia and PC groups were significantly higher than those in active TB and MP infection groups(χ²=308.5, P=0.012). The changing trends of PCT concentrations in different groups were as follows: bacterial pneumonia≈PC>active TB>MP infection/viral infection≈control group. ROC curve indicated that at the cut-off values of 0.48 ng/mL and 0.10 ng/mL PCT could best differentiate bacterial pneumonia and PC from active TB and MP infection, respectively. Conclusion The serum PCT concentration, if at higher level, could be used as an effective means in differentiating pulmonary infections in the elderly populations, but if it was at slightly increased level, it might be caused by various microbiological pathogens that would reduce its clinical value and limit its utility.

Key words: pulmonary infection, procalcitonin, bacteremia

CLC Number:

Lu Binghuai, Shi Yanli, Li Xueqing, ZHU Fengxia, Xia Lijiao, Shi Lina, Zhao Hua. Clinical utility of serum procalcitonin in differentiation of pulmonary infections in the elderly populations[J]. Journal of Capital Medical University, 2014, 35(4): 456-462.

0
/ Save 0 / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2014.04.015

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2014/V35/I4/456

References

[1] Gilbert D N. Use of plasma procalcitonin levels as an adjunct to clinical microbiology[J]. J Clin Microbiol, 2010,48(7):2325-2329.
[2] Becker K L, Snider R, Nylen E S. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations[J]. Crit Care Med, 2008,36(3):941-952.
[3] Horan T C, Andrus M, Dudeck M A. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting[J]. Am J Infect Control, 2008,36(5):309-332.
[4] 中华医学会结核病学分会.肺结核诊断和治疗指南[J].中华结核和呼吸杂志,2001,24(2):70-74.
[5] Levy M M, Fink M P, Marshall J C, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference[J]. Crit Care Med, 2003,31(4):1250-1256.
[6] 中华医学会呼吸病学分会.社区获得性肺炎诊断和治疗指南[J].中华结核和呼吸杂志,2006,29(10):651-655.
[7] 付娟娟,李娟.老年糖尿病合并肺部感染的健康教育[J].解放军医药杂志,2011,23(s1):149-150.
[8] 欧海强.沐舒坦治疗老年人肺部感染的疗效观察及危险因素分析[J].中国煤炭工业医学杂志,2013,16(7):1065-1066.
[9] Moulin F, Raymond J, Lorrot M, et al. Procalcitonin in children admitted to hospital with community acquired pneumonia[J]. Arch Dis Child, 2001,84(4):332-336.
[10] Michelow I C, Olsen K, Lozano J, et al. Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children[J]. Pediatrics, 2004,113(4):701-707.
[11] Jereb M, Kotar T. Usefulness of procalcitonin to differentiate typical from atypical community-acquired pneumonia[J]. Wien Klin Wochenschr, 2006,118(5-6):170-174.
[12] Becker K L, Snider R, Nylen E S. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations[J]. Crit Care Med, 2008,36(3):941-952.
[13] Shimetani N, Shimetani K, Mori M. Clinical evaluation of the measurement of serum procalcitonin: comparative study of procalcitonin and serum amyloid A protein in patients with high and low concentrations of serum C-reactive protein[J]. Scand J Clin Lab Invest, 2004,64(5):469-474.
[14] Petrikkos G L, Christofilopoulou S A, Tentolouris N K, et al. Value of measuring serum procalcitonin, C-reactive protein, and mannan antigens to distinguish fungal from bacterial infections[J]. Eur J Clin Microbiol Infect Dis, 2005,24(4):272-275.
[15] Charles P E, Dalle F, Aho S, et al. Serum procalcitonin measurement contribution to the early diagnosis of candidemia in critically ill patients[J]. Intensive Care Med, 2006,32(10):1577-1183.
[16] Kang Y A, Kwon S Y, Yoon H I, et al. Role of C-reactive protein and procalcitonin in differentiation of tuberculosis from bacterial community acquired pneumonia[J]. Korean J Intern Med, 2009,24(4):337-342.
[17] Baylan O, Balkan A, Inal A, et al. The predictive value of serum procalcitonin levels in adult patients with active pulmonary tuberculosis[J]. Jpn J Infect Dis, 2006,59(3):164-167.
[18] 刘玉玲,赵小慧,张克武.降钙素原与超敏C-反应蛋白在慢性阻塞性肺疾病急性加重期中的临床意义[J].中国煤炭工业医学杂志,2012,15(9):1384-1385.